Schizophrenia-Psychotic Disorders & Antipsychotics

 (Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

 

3 - Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review

David Taylor

The British Journal of Psychiatry (2009) 195: S13-S19

 

5 - First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies

Peter M. Haddad, Mark Taylor, Omair S. Niaz

The British Journal of Psychiatry (2009) 195: S20-S28

 

3! - Second-generation antipsychotic long-acting injections: systematic review

W. Wolfgang Fleischhacker

The British Journal of Psychiatry (2009) 195: S29-S36

3! - Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia

Luisa Tomelleri, Jigar Jogia, Cinzia Perlini, Marcella Bellani, Adele Ferro, Gianluca Rambaldelli, Michele Tansella, Sophia Frangou, Paolo Brambilla and The Neuroimaging Network of the ECNP networks initiative

European Neuropsychopharmacology. Volume 19, Issue 12, December 2009, Pages 835-840

 

3 - BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D₂ receptor occupancy study in humans

Lieuwe Appel, Yona Geffen, Kerstin Heurling, Catarina Eriksson, Gunnar Antoni and Shitij Kapur

European Neuropsychopharmacology. Volume 19, Issue 12, December 2009, Pages 841-850

 

3 - Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: A possible role of α1-adrenoceptors

Yuko Tanibuchia, Yuko Fujita, Mami Kohno, Tamaki Ishima, Yuto Takatsu, Masaomi Iyo and Kenji Hashimoto

European Neuropsychopharmacology. Volume 19, Issue 12, December 2009, Pages 861-867

 

GRATIS 3 - A translational research approach to poor treatment response in patients with schizophrenia: clozapine–antipsychotic polypharmacy

William G. Honer, Ric M. Procyshyn, Eric Y.H. Chen, G. William MacEwan, Alasdair M. Barr

J Psychiatry Neurosci 2009;34(6):433-42

 

3 - Bipolar II Postpartum Depression: Detection, Diagnosis, and Treatment

Verinder Sharma, Vivien K. Burt, and Hendrica L. Ritchie

Am J Psychiatry 166:1217-1221, November 2009

3! - Association of Pre-Onset Cannabis, Alcohol, and Tobacco Use With Age at Onset of Prodrome and Age at Onset of Psychosis in First-Episode Patients

Michael T. Compton, Mary E. Kelley, Claire E. Ramsay, Makenya Pringle, Sandra M. Goulding, Michelle L. Esterberg, Tarianna Stewart, and Elaine F. Walker

Am J Psychiatry 2009; 166:1251-1257

3 - Pharmacokinetic and Pharmacodynamic Interactions Between Carbamazepine and Aripiprazole in Patients With Schizophrenia

Nakamura, Akifumi; Mihara, Kazuo; Nagai, Goyo; Suzuki, Takeshi; Kondo, Tsuyoshi

Therapeutic Drug Monitoring: October 2009 - Volume 31 - Issue 5 - pp 575-578

 

3 - Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia: A Population-Based Nested Case-Control Study

Lone Baandrup, Christiane Gasse, Vibeke D. Jensen, Birte Y. Glenthoj, Merete Nordentoft, Henrik Lublin, Anders Fink-Jensen, Anne Lindhardt, and Preben B. Mortensen

J Clin Psychiatry. Online ahead of print: November 3, 2009

 

5 - A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia

Yechiel Levkovitz, Shlomo Mendlovich, Sharon Riwkes; Yoram Braw, Hana Levkovitch-Verbin, Gilad Gal, Shmuel Fennig, Ilan Treves, and Shmuel Kron

J Clin Psychiatry. Online ahead of print: November 3, 2009

 

3 - Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial

S. Englisch, U. Knopf, B. Scharnholz, A. Kuwilsky, M. Deuschle, M. Zink

Journal of Psychopharmacology, Vol. 23, No. 8, 875-882 (2009)

 

3 - Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up

V. Medved, MR Kuzman, N. Jovanovic, J. Grubisin, T. Kuzman

Journal of Psychopharmacology, Vol. 23, No. 8, 915-922 (2009)

 

3! - Outcomes for schizophrenia patients with clozapine treatment: how good does it get?

A. Wheeler, V. Humberstone, G. Robinson

Journal of Psychopharmacology, Vol. 23, No. 8, 957-965 (2009)

 

3 - Molecular mechanisms underlying synergistic effects of SSRI–antipsychotic augmentation in treatment of negative symptoms in schizophrenia

Yael Chertkow, Orly Weinreb, Moussa B. H. Youdim and Henry Silver

Journal of Neural Transmission. Volume 116, Number 11 / November, 2009: 1529-1541

 

5 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

John M. Kane, Christoph U. Correll, Donald C. Goff, Brian Kirkpatrick, Stephen R. Marder, Estelle Vester-Blokland, Wei Sun, William H. Carson, Andrei Pikalov, and Sheila Assunção-Talbott

J Clin Psychiatry 2009;70(10):1348–1357

 

3 - A Randomized Controlled Trial of Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia Patients: Initial Adherence Outcome

Peter J. Weiden, Nina R. Schooler, Jeremy C. Weedon, Abdel Elmouchtari, Ayako Sunakawa, and Stephen M. Goldfinger

J Clin Psychiatry 2009;70(10):1397–1406

 

5< - Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial With Memantine as Add-On Therapy to Clozapine

David de Lucena, Brisa Simões Fernandes, Michael Berk, Seetal Dodd, Dalton W. Medeiros, Mariana Pedrini, Mauricio Kunz, Fabiano Alves Gomes, Larriany F. Giglio, Maria Inês Lobato, Paulo Silva Belmonte-de-Abreu, and Clarissa Severino Gama

J Clin Psychiatry 2009;70(10):1416–1423

 

3 - Lurasidone: a new drug in development for schizophrenia

Jonathan M Meyer ‌, Antony D Loebel & Edward Schweizer

Expert Opinion on Investigational Drugs. November 2009, Vol. 18, No. 11, Pages 1715-1726

 

3! - Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics

Alexander Brunnauer, Gerd Laux and Sarah Zwick

European Archives of Psychiatry and Clinical Neuroscience. Volume 259, Number 8 / December, 2009: 483-489

 

3! - Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study

Jonathan M. Meyer, Joseph P. McEvoy, Vicki G. Davis, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, John K. Hsiao, Marvin S. Swartz, T. Scott Stroup and Jeffrey A. Lieberman

Biological Psychiatry. Volume 66, Issue 11, 1 December 2009, Pages 1013-1022 

3! - Clozapine Administration in Adolescence Prevents Postpubertal Emergence of Brain Structural Pathology in an Animal Model of Schizophrenia

Yael Piontkewitz, Yaniv Assaf and Ina Weiner

Biological Psychiatry. Volume 66, Issue 11, 1 December 2009, Pages 1038-1046 

3 - Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics

Mei Hong Xiu, Li Hui, Yu Feng Dang, Tian De Hou, Chong Xi Zhang, You Lan Zheng, Da Chun Chen, Thomas R. Kosten and Xiang Yang Zhang

Progress in Neuro-Psychopharmacology and Biological Psychiatry. Volume 33, Issue 8, 13 November 2009, Pages 1508-1512 

5 - Mifepristone treatment of olanzapine-induced weight gain in healthy men

Mifepristone treatment of olanzapine-induced weight gain in healthy men

Advances in Therapy. On-Line First, November 2009

 

3 - Modulation of Limbic Circuitry Predicts Treatment Response to Antipsychotic Medication: A Functional Imaging Study in Schizophrenia

Adrienne C Lahti, Martin A Weiler, Henry H Holcomb, Carol A Tamminga and Karen L Cropsey

Neuropsychopharmacology (2009) 34, 2675–2690

 

3! - Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice: Findings From the CLAMORS Study

Julio Bobes, Celso Arango, Margarida Garcia-Garcia, and Javier Rejas, for the CLAMORS Study Collaborative Group

J Clin Psychiatry. Online ahead of print: November 3, 2009

 

3! - Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring

A. Sparshatt, D. Taylor, M. X. Patel and S. Kapur

Acta Psychiatrica Scandinavica. Volume 120 Issue 6, Pages 416 - 428

 

3! - Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)

Han Boter, Joseph Peuskens, Jan Libiger, W. Wolfgang Fleischhacker, Michael Davidson, Silvana Galderisi, René S. Kahn and for the EUFEST study group

Schizophrenia Research. Volume 115, Issues 2-3, December 2009, Pages 97-103

 

3! - Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

Leslie Citrome, Christopher Reist, Liisa Palmer, Leslie B. Montejano, Gregory Lenhart, Brian Cuffel, James Harnett and Kafi N. Sanders

Schizophrenia Research. Volume 115, Issues 2-3, December 2009, Pages 115-120

 

3! - Symptomatic and functional outcome in youth at ultra-high risk for psychosis: A longitudinal study

Serafín Lemos-Giráldez, Oscar Vallina-Fernández, Purificación Fernández-Iglesias, Guillermo Vallejo-Seco, Eduardo Fonseca-Pedrero, Mercedes Paíno-Piñeiro, Susana Sierra-Baigrie, Pilar García-Pelayo, Clara Pedrejón-Molino, Sandra Alonso-Bada, Ana Gutiérrez-Pérez and Jose Angel Ortega-Ferrández

Schizophrenia Research. Volume 115, Issues 2-3, December 2009, Pages 121-129

 

3 - Biochemical risk factors for development of obesity in first-episode schizophrenia

Robert Bodén, Arvo Haenni, Leif Lindström and Johan Sundström

Schizophrenia Research. Volume 115, Issues 2-3, December 2009, Pages 141-145

 

3 - The relationship between prepulse inhibition and general psychopathology in patients with schizophrenia treated with long-acting risperidone

Isabel Martinez-Gras, Gabriel Rubio, Blanca Alvarez del Manzano, Roberto Rodriguez-Jimenez, Fernando Garcia-Sanchez, Alexandra Bagney, Juan Carlos Leza and José Borrell

Schizophrenia Research. Volume 115, Issues 2-3, December 2009, Pages 215-221 

3! - Twin study of illness history variables in psychosis

Charlotte L. Allan, Alastair G. Cardno, Frühling V. Rijsdijk, Sridevi Kalidindi, Anne Farmer, Robin M. Murray and Peter McGuffin

Schizophrenia Research. Volume 115, Issues 2-3, December 2009, Pages 237-244

 

3 - The psychoses: Cluster 3 of the proposed meta-structure for DSM-V and ICD-11

W. T. Carpenter Jr., J. R. Bustillo, G. K. Thaker, J. van Os, R. F. Krueger and M. J. Green

Psychological Medicine (2009), 39:2025-2042

 

3! - Improved Body Weight and Metabolic Outcomes in Overweight or Obese Psychiatric Patients Switched to Amisulpride From Other Atypical Antipsychotics

Lin, Chao-Cheng; Bai, Ya-Mei; Wang, Ying-Chieh; Chen, Tzu-Ting; Lai, I-Ching; Chen, Jen-Yeu; Chen, Shiow-Yi; Gau, Susan S.F; Liou, Ying-Jay

Journal of Clinical Psychopharmacology: December 2009 - Volume 29 - Issue 6 - pp 529-536

 

3 - Impact of CYP2D6 Genotype on Steady-State Serum Concentrations of Risperidone and 9-Hydroxyrisperidone in Patients Using Long-Acting Injectable Risperidone

Hendset, Magnhild; Molden, Espen; Refsum, Helge; Hermann, Monica

Journal of Clinical Psychopharmacology: December 2009 - Volume 29 - Issue 6 - pp 537-541

 

3! - Onset and Persistence of Antipsychotic Response in Patients With Schizophrenia

Glick, Ira D; Bossie, Cynthia A; Alphs, Larry; Canuso, Carla M

Journal of Clinical Psychopharmacology: December 2009 - Volume 29 - Issue 6 - pp 542-547

 

3 - D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia

Uchida, Hiroyuki; Rajji, Tarek K; Mulsant, Benoit H; Kapur, Shitij; Pollock, Bruce G; Graff-Guerrero, Ariel; Menon, Mahesh; Mamo, David C

Journal of Clinical Psychopharmacology: December 2009 - Volume 29 - Issue 6 - pp 571-575

 

3 - 30 Days of Continuous Olanzapine Infusion Determines Energy Imbalance, Glucose Intolerance, Insulin Resistance, and Dyslipidemia in Mice

Coccurello, Roberto; Brina, Daniela; Caprioli, Antonio; Conti, Roberto; Ghirardi, Orlando; Schepis, Filippo; Moles, Anna

Journal of Clinical Psychopharmacology: December 2009 - Volume 29 - Issue 6 - pp 576-583

 

3 - Can the Sigma-1 Receptor Agonist Fluvoxamine Prevent Schizophrenia?

Hashimoto, Kenji

CNS & Neurological Disorders - Drug Targets, Volume 8, Number 6, December 2009 , pp. 470-474(5)

 

3 - Roles of the Akt/GSK-3 and Wnt Signaling Pathways in Schizophrenia and Antipsychotic Drug Action

Zachary Freyberg, Stephen J. Ferrando, and Jonathan A. Javitch

Am J Psychiatry Published November 16, 2009

3! - Early- and Delayed Antipsychotic Response and Prediction of Outcome in 528 Severely Impaired Patients with Schizophrenia Treated with Amisulpride

M. Lambert, B. G. Schimmelmann, D. Naber, F.-X. Eich, H. Schulz, C. G. Huber, A. Karow

Pharmacopsychiatry 2009; 42: 277-283

3 - Effects of Olanzapine and Haloperidol on the Metabolic Status of Healthy Men

Solrun Vidarsdottir, Judith E. de Leeuw van Weenen, Marijke Frölich, Ferdinand Roelfsema, Johannes A. Romijn, and Hanno Pijl

Journal of Clinical Endocrinology & Metabolism , October 19, 2009

 

3! - Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents

Pål Gjerden, Lars Slørdal and Jørgen G. Bramness

European Journal of Clinical Pharmacology. Volume 65, Number 12 / December, 2009: 1229-1235

 

4 - Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean?

David B. Allison, Antony D. Loebel, Ilise Lombardo, Steven J. Romano and Cynthia O. Siu

Psychiatry Research. Volume 170, Issues 2-3, 30 December 2009, Pages 172-176

 

3 - The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series

Se Hyun Kim, Dong Chung Jung, Yong Min Ahn, and Yong Sik Kim

Journal of Psychopharmacology. First published on November 26, 2009

3 - Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia

Takefumi Suzuki, Hiroyuki Uchida, Hiroyoshi Takeuchi, Shinichiro Nakajima, Kensuke Nomura, Akira Tanabe, Gohei Yagi, Koichiro Watanabe, Haruo Kashima

Human Psychopharmacology: Clinical and Experimental. Volume 24 Issue 8, Pages 628 - 638

 

3! - Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study

M. Jäger, M. Schmauß, G. Laux, H. Pfeiffer, D. Naber, L. G. Schmidt, W. Gaebel, J. Klosterkötter, I. Heuser, W. Maier, M.R. Lemke, D. Degner, G. Buchkremer, M. Gastpar, H.-J. Möller and M. Riedel

European Psychiatry. Volume 24, Issue 8, December 2009, Pages 501-506

 

3 - ECT rekindles pharmacological response in schizophrenia

H. Hustig and R. Onilov

European Psychiatry. Volume 24, Issue 8, December 2009, Pages 521-525

 

3 - Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance

Benjamin Guesdon, Raphaël G.P. Denis and Denis Richard

Behavioural Brain Research. Volume 207, Issue 1, 11 February 2010, Pages 14-20

 

3 - Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea

Susanne Steinlechner, Christine Klein, Andreas Moser, Rebekka Lencer and Johann Hagenah

Psychopharmacology. Volume 207, Number 4 / January, 2010: 593-597

 

3 - From bench to bedside: translating new research from genetics and neuroimaging into treatment development for early-onset schizophrenia

Sanjiv Kumra, Robert Asarnow, Anthony Grace, Matcheri Keshavan, Jon McClellan, Linmarie Sikich and Ann Wagner

Early Intervention in Psychiatry. Volume 3 Issue 4, Pages 243 - 258

 

3 - 'Schizophrenia postdrome': a study of low-level psychotic experience after remission of first-episode schizophrenia

Kate Burley, Rachel Upthegrove, Max Birchwood, Paul Patterson and Amanda Skeate

Early Intervention in Psychiatry. Volume 3 Issue 4, Pages 296 - 299

 

3 - Risperidone long acting injection: Findings of a 2-year retrospective follow-up study

Paul N. Deslandes;  Anna Lewis;  Arwel Thomas; Robert D. E. Sewell

International Journal of Psychiatry in Clinical Practice, Volume 13, Issue 4 November 2009, pages 298 - 302

 

3 - The prevalence of comorbid anxiety disorders in outpatients with schizophrenia

Melike Nebioglu; Abdurrahman Altindag

International Journal of Psychiatry in Clinical Practice, Volume 13, Issue 4 November 2009, pages 312 - 317

 

GRATIS (previo registro) 3! - Estabilidad diagnóstica y pronóstico a dos años de episodios psicóticos agudos

A. Pedrós,  J. Martí,  G. Gutiérrez,  J. M. Tenías y S. Ruescas

Actas Esp Psiquiatr 2009;37(5):245-251

 

GRATIS 5< - Effect of the Selective Norepinephrine Reuptake Inhibitor Reboxetine on Cognitive Dysfunction in Schizophrenia Patients: An Add-on, Double-Blind Placebo-Controlled Study

Michael Poyurovsky, Sarit Faragian, Camil Fuchs, and Artashez Pashinian,

Isr J Psychiatry Relat Sci Vol 46 No. 3 (2009) 213–220

 

Regresar a RESÚMENES NOVIEMBRE 2009